I will introduce a number of computational tools and analyses focusing on data from large-scale genetic-perturbation/drug-screens performed across panels of immortalised cancer in-vitro models, their integration with the multi-omic characterisation of these models, and data from public cancer genomics repositories. The aim of these analyses is to identify new oncology therapeutic biomarkers, new therapeutic targets, drug repositioning opportunities and new somatic variants of clinical relevance. I will present results and methods designed and implemented by my research team, as well as I will discuss related computational challenges and possible ways to tackle them.